Scientists test new drug duo in fight against tough cancers
NCT ID NCT01445509
Summary
This early-stage study aimed to find the safest dose of a two-drug combination (dasatinib and bevacizumab) for treating advanced solid tumors. It involved 50 adults whose cancers had stopped responding to standard therapies. The main goal was to understand the side effects and determine the highest dose patients could tolerate, while also checking if the drugs showed any early signs of slowing cancer growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.